MBX Biosciences, Inc. Common Stock reports a Return on Equity (ROE) of -19.78%.

What is MBX's dividend yield?

MBX Biosciences, Inc. Common Stock offers a dividend yield of 0.00%.

What is MBX's Quality Score?

Our AI rates MBX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy MBX?

Our AI Timing Score for MBX is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does MBX belong to?

MBX Biosciences, Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

MBX Biosciences, Inc. (MBX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

MBX AI Analysis Summary

Our AI summary for MBX: MBX Biosciences, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -19.78%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

MBX

MBX Biosciences, Inc. Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology News 88

USD 64.41

-1.52 (-2.31%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-19.8%

ROE

-19.1%

ROA

0.00%

Div Yield

MBX BIOSCIENCES, INC. COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 64.41 Price -1.52 (-2.31%) Day Change	NEWS SCORE: 88

MBX, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

38%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	88
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	64.41
PBV / Sector	7.17 / 44,219.29
Earning Per Share	-1.78

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	44.20 M GREAT
Average 1W Daily Value	32.29 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.22
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-19.13 / 185,260.96
ROA Average (%) / Sector	-32.28 / 36,684.70
ROA Change Average (%) / Sector	-22.75 / 422,221.66
ROE (%) / Sector	-19.78 / 243,762.23
ROE Average (%) / Sector	7.78 / 48,758.47
ROE Change Average (%) / Sector	-49.59 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:50
Symbol	MBX
Name	MBX BIOSCIENCES, INC. COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	47.60 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	3,138.11 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 11711 North Meridian Street, Carmel, IN, United States, 46032

Phone: 317 659 0200

Website: https://mbxbio.com

Employees: 63

Sector: Healthcare >> Biotechnology

Description: MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.